Development of a novel nanoliter scale total antibody (TAb) assay to detect pre-existing antibodies against AAV vectors regardless of serotype
In clinical trials using adeno-associated virus (AAV) vectors for gene therapy, it is critical to pre-screen participants to ensure they don't have pre-existing neutralizing antibodies (NAbs). Both humans and non-human primates (NHPs) can naturally carry such antibodies, making screening essential prior to AAV vector administration.
Gyros Protein Technologies has developed a novel anti-AAV total antibody (TAb) immunoassay using the automated Gyrolab platform. This assay overcomes traditional challenges by detecting anti-AAV antibodies in human and NHP samples without the need for serotype-specific assays or AAV capsid labeling.
Download this poster to learn how you can:- Move away from labor-intensive NAb assays and restrictive TAb methods.
- Leverage Gyrolab technology: Implement a universal screening approach for multiple AAV serotypes.
- Validate results: Ensure accuracy in both human and NHP samples for consistent data.
- Improve clinical and preclinical research: Improve trial participant selection and streamline immunogenicity screening workflows with validated protocols.
This innovative approach can significantly streamline and enhance your screening processes, increasing the efficiency and accuracy of gene therapy trials.
If you have problems downloading the poster, please contact maritha.lundin@gyrosproteintech.com